Gilead Financial Statements From 2010 to 2024
| GILD34 Stock | BRL 287.56 4.47 1.58% |
Check Gilead Sciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gilead Sciences' main balance sheet or income statement drivers, such as , as well as many indicators such as . Gilead financial statements analysis is a perfect complement when working with Gilead Sciences Valuation or Volatility modules.
Gilead |
Gilead Sciences Company Profit Margin Analysis
Gilead Sciences' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Gilead Sciences Profit Margin | 0.17 % |
Most of Gilead Sciences' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gilead Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Gilead Sciences has a Profit Margin of 0.1683%. This is 101.5% lower than that of the Healthcare sector and 98.92% lower than that of the Drug Manufacturers - Major industry. The profit margin for all Brazil stocks is 113.25% lower than that of the firm.
Gilead Sciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Gilead Sciences's current stock value. Our valuation model uses many indicators to compare Gilead Sciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gilead Sciences competition to find correlations between indicators driving Gilead Sciences's intrinsic value. More Info.Gilead Sciences is rated # 4 in return on equity category among its peers. It is rated # 3 in return on asset category among its peers reporting about 0.48 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Gilead Sciences is roughly 2.07 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Gilead Sciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Gilead Sciences' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Gilead Sciences Financial Statements
Gilead Sciences stakeholders use historical fundamental indicators, such as Gilead Sciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Gilead Sciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Gilead Sciences' assets and liabilities are reflected in the revenues and expenses on Gilead Sciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Gilead Sciences. Please read more on our technical analysis and fundamental analysis pages.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. GILEAD DRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 11000 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Gilead Stock
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out the analysis of Gilead Sciences Correlation against competitors. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.